Pirenzepine

DB00670

small molecule approved

Deskripsi

An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients.

Struktur Molekul 2D

Berat 351.4023
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take on an empty stomach. Take pirenzepine at least 30 minutes before meals.

Interaksi Obat

516 Data
Aclidinium The risk or severity of adverse effects can be increased when Pirenzepine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Pirenzepine.
Mirabegron The risk or severity of urinary retention can be increased when Pirenzepine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Pirenzepine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Pirenzepine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Pirenzepine.
Tiotropium The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Pirenzepine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Pirenzepine is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum toxin type A.
Glucagon Pirenzepine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Pirenzepine may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Pirenzepine is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Pirenzepine is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Pirenzepine is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Pirenzepine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Pirenzepine is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Pirenzepine is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Pirenzepine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Pirenzepine is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Pirenzepine is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Pirenzepine is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Pirenzepine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Pirenzepine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Pirenzepine is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Pirenzepine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Pirenzepine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Pirenzepine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Pirenzepine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Pirenzepine is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Pirenzepine is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Pirenzepine is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Pirenzepine is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Pirenzepine.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pirenzepine.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Pirenzepine.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Pirenzepine.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Pirenzepine.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Pirenzepine.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Pirenzepine.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pirenzepine.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Pirenzepine.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Pirenzepine.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pirenzepine.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Pirenzepine.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Pirenzepine.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Pirenzepine.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Pirenzepine.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Pirenzepine.
Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Pirenzepine is combined with Homatropine methylbromide.
Benzquinamide The risk or severity of adverse effects can be increased when Pirenzepine is combined with Benzquinamide.
Propantheline The risk or severity of adverse effects can be increased when Pirenzepine is combined with Propantheline.
Dicyclomine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dicyclomine.
Tropicamide The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tropicamide.
Cocaine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Cocaine.
Quinidine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Quinidine.
Amantadine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Amantadine.
Methantheline The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methantheline.
Cycrimine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Cycrimine.
Cyclopentolate The risk or severity of adverse effects can be increased when Pirenzepine is combined with Cyclopentolate.
Tolterodine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tolterodine.
Oxybutynin The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.
Pentolinium The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Pirenzepine is combined with Trimethaphan.

Target Protein

Muscarinic acetylcholine receptor M1 CHRM1

Referensi & Sumber

Artikel (PubMed)

Contoh Produk & Brand

Produk: 1 • International brands: 22
Produk
  • Gastrozepin Tab 50mg
    Tablet • 50 mg / tab • Oral • Canada • Approved
International Brands
  • Anquwei — Panion & BF
  • Folinzepin — Tsuruhara Seiyaku
  • Garendopine — Choseido Pharmaceutical
  • Gaspin — Gentle
  • Gastrozepin — Boehringer Ingelheim
  • Gastsion — Shiono Kemikaru
  • Gaszepin — Swiss Pharm
  • Karoderin — Nippon Chemiphar
  • Kawaipin — Siu Guan
  • Kiccalzin — Takata Seiyaku

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul